宜明昂科-B(01541) - 2023 - 中期业绩

Financial Results - ImmuneOnco Biopharmaceuticals reported its interim financial results for the six months ended June 30, 2023, in accordance with International Accounting Standard 34[1] - The company will not publish an independent interim report or summary report for the six months ended June 30, 2023, as it is included in the prospectus dated August 24, 2023[2] Board of Directors - The board of directors consists of three executive directors, three non-executive directors, and three independent non-executive directors[2]